Bluefish raises approximately SEK 28 million in new capital
Bluefish Pharmaceuticals has completed a successful capital raising of approximately SEK 28 million in new capital from a number of new investors. The new capital will be used to continue the European expansion and confirms a continued strong interest for Bluefish and its business modelNordea Bank has acted financial adviser.For further information:Bluefish PharmaceuticalsKarl Karlsson, President and CEO, tel +46 8 679 50 70Susanna Urdmark, Executive VP, Global Product Strategy, tel +46 8 679 50 70Bluefish PharmaceuticalsBluefish Pharmaceuticals AB is a Swedish pharmaceutical